BioSpace News Archive

Allogene Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma.

electroCore, Inc. today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a public offering price of $1.00 per share.

Cerus Announces Collaboration with LifeSouth Community Blood Centers to Manufacture INTERCEPT ® Fibrinogen Complex

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 5, 2021.

ReShape Lifesciences Inc., a global physician-led weight-loss and metabolic health solutions company, provided additional information about its previously announced warrant exercise agreement with existing accredited investors for approximately $46 million in gross proceeds.

Delic Corp today announced that its subsidiary, DELIC Labs , has entered into a partnership agreement with Agilent, a global leader in life sciences, diagnostics, and applied chemical markets.

SELLAS Life Sciences Group, Inc today announced promising updated clinical data and initial immunobiological data from its Phase 1/2 clinical trial with its lead asset, galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with the checkpoint inhibitor pembrolizumab (Keytruda®).

DCN Dx, an international provider of point-of-care diagnostics development, products, and educational programming, today announced it has completed its acquisition of IVD Vision, Inc., a developer of custom instruments and software for diagnostics systems based here.

Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that David K. Erickson has joined the company as Vice President, Investor Relations where he will be responsible for developing, implementing and managing a comprehensive and strategic investor relations program.

Novome Biotechnologies, Inc.today announced the start of a Phase 1 clinical trial of NOV-001.